Data from the OCARINA II trial shows that a 10-minute subcutaneous injection of Ocrevus achieves similar pharmacokinetics as the typical hours-long intravenous infusion in multiple sclerosis patients.
https://www.pharmalive.com/wp-content/uploads/2020/03/Roche-Phase-III-RA-Drug-For-COVID-19-Pneumonia-BioSpace-3-19-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-07-13 10:06:392023-07-13 10:06:39Roche’s Ocrevus subcutaneous injection matches IV infusion in Phase III MS trial
